Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieve ...

A separate, simplified model compared the biologic dupilumab to PPI and tCS. The primary outcome was the incremental cost-effectiveness ratio (ICER) at 2- and 5-year time horizons. Treatment ...

If approved, potential barriers to the use of dupilumab in practice include cost and insurance coverage, education and dissemination of study findings, and limited data on side effects ...

Dupixent (dupilumab) is a prescription drug that ... Also, be sure to talk with your doctor about which drug is better for you. Costs of prescription drugs can vary depending on many factors.

Dupilumab users had at least 0.5 fewer exacerbations ... Overall increases in asthma-related costs associated with the use of these biologic treatments likely reflect the costs of these drugs ...

Dupilumab dosing was changed from every 2 weeks ... that almost half of the patients tolerated less-frequent dosing. Given the high cost of biologics and the need for injections, these data ...

additional costs applied to non-responders to account for the cost of treatment failure (see section 3.12). When taking into account the confidential discount for dupilumab, the company's base-case ...

Dupilumab and topical corticosteroids can be ... Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

These medications include benralizumab and dupilumab injections. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that occurs when the air sacs in the lungs lose elasticity or ...

Dupilumab (Dupixent): This newer medication ... That’s lucky, since phototherapy regimens can cost several thousand dollars. Don’t let the costs of managing your atopic dermatitis treatment ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...